Plain-English translation of NCT01409161 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications — (a vitamin A derivative), , and (a targeted antibody) — to treat acute promyelocytic leukemia (APL), a rare type of blood cancer. The study aims to see whether this combination can help people with newly diagnosed APL go into complete remission and stay healthy long-term. The choice to add the third medication depends on how many white blood cells you have when diagnosed.
APL is a serious blood cancer that needs fast treatment, but doctors want to find the best medication combinations that work well without causing too many side effects. This trial is testing whether adding a newer medication to the standard two-drug approach can improve outcomes, especially for patients at higher risk.
You likely qualify if…
You likely don't qualify if…
You would first receive an intensive treatment phase (induction) lasting several weeks, where you take one medication by mouth twice daily and receive the other two medications by IV infusion. If you respond well, you then enter a consolidation phase lasting several months with a repeating 8-week cycle of treatment. Throughout the study, you would have regular blood tests and clinic visits to monitor your health and how well the treatment is working, with follow-up appointments continuing for years after treatment ends.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States